查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
青光眼治療市場規模和預測、全球和地區佔有率、趨勢和成長機會分析報告範圍：按藥物類別、適應症、配銷通路和地理位置
市場調查報告書
商品編碼
1535259

青光眼治療市場規模和預測、全球和地區佔有率、趨勢和成長機會分析報告範圍：按藥物類別、適應症、配銷通路和地理位置

Glaucoma Therapeutics Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Drug Class, Indication, Distribution Channel, and Geography
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 訂單完成後即時交付

價格

2023年青光眼治療市場估值為62.4億美元，預計2031年將達80.2億美元；預計 2023 年至 2031 年複合年成長率為 3.2%。

推動市場成長的關鍵因素是青光眼盛行率的不斷上升、對該疾病的認知和早期診斷的提高以及產品發布的增加預計將推動市場成長。然而，藥物治療的依從性問題和高昂的治療成本阻礙了青光眼治療市場的成長。

青光眼治療市場的市場趨勢：

主要由於老化而導致的視神經逐漸損傷（通常與眼內高壓（眼內壓）有關）會導致一組稱為青光眼的眼部疾病，最終導致不可逆的失明。青光眼最常見的治療方法之一是使用眼藥水降低眼內壓。然而，患者堅持使用這些眼藥水可能具有挑戰性，患者教育不足可能會阻礙治療成功。此外，降眼壓藥物可能引起局部和全身副作用，可能使治療更加複雜。人們日益關注開發具有更高穩定性、更長循環時間和有針對性的結合特性的改進配方，這可能會為市場帶來新產品。青光眼治療的最新進展徹底改變了市場上可用的治療方法。使用具有合適結構和優異結合能力的奈米顆粒有利於藥物的生物利用度和功效。與傳統眼藥水相比，緩釋 (SR) 植入物和其他創新藥物傳遞系統可提高患者依從性並減少副作用。多家公司正在開發 SR 藥物輸送系統，作為局部給藥的替代方案，以潛在克服治療 POAG 的障礙。根據 2022 年 PubMed Central 發表的文章，美國食品藥物管理局 (FDA) 唯一批准的 POAG SR 療法是 Allergan plc 的 Bimatoprost SR (DurystaTM)。其他SR 療法包括比馬前列素眼環(Allergan)、iDose (Glaukos Corporation)、ENV515 (Envisia Therapeutics)、OTX-TP (Oural Therapeutix)、OTX-TIC (Oural Therapeutix) 和拉坦前列素遊離酸SR (SR ( PolyActiva) 正在研究中。 POAG 管理中的 SR 給藥技術可能會改變治療模式並顯著改善結果。因此，新型藥物傳輸方法和聯合療法的開發可能仍然是青光眼治療市場的主要趨勢。

青光眼治療市場：細分概述

青光眼治療市場根據藥物類別、適應症和配銷通路進行細分。

依藥物類別，市場分為BETA受體阻斷劑、α-腎上腺素激動劑、前列腺素類似物、碳酸酐酶抑制劑、合併藥物等。到2023年，前列腺素類似物細分市場將佔據更大的市場佔有率。它們每天給藥一次，可顯著降低眼壓，全身副作用較低。因此，前列腺素類似物的好處是青光眼治療市場規模擴大的原因。

依適應症，市場分為開角型青光眼、閉角型青光眼等。開角型青光眼細分市場在 2023 年佔據最大的青光眼治療市場佔有率，預計 2023 年至 2031 年複合年成長率最高。最初，它沒有表現出任何症狀。然而，在某些時候，一個人可能會在不接受治療的情況下開始失去側面（周邊）視力，導致完全失明。

依配銷通路，市場分為醫院藥房、零售藥房和網路藥房。 2023年，醫院藥局領域佔據市場主導地位。

青光眼治療市場：地理概況

青光眼治療市場報告的範圍涉及北美（美國、加拿大和墨西哥）、歐洲（西班牙、英國、德國、法國、義大利和歐洲其他地區）、亞太地區（韓國、中國、印度） 、日本、澳洲和亞太其他地區）、中東和非洲（南非、沙烏地阿拉伯、阿拉伯聯合大公國以及中東和非洲其他地區）以及南美洲和中美洲（巴西、阿根廷和其他地區）南美洲和中美洲）。預計從2023 年到2031 年，亞太地區的複合年成長率將是市場上最快的。 正在進行的開發新型青光眼療法的臨床研究以及該地區醫療保健支出的增加等因素將促進亞太地區青光眼治療市場的成長。就收入而言，北美在 2023 年佔據最大的青光眼治療市場。

目錄

第 1 章：簡介

第 2 章：執行摘要

  • 主要見解

第 3 章：研究方法

  • 二次研究
  • 初步研究
    • 假設表述：
    • 宏觀經濟因素分析：
    • 顯影基數：
    • 數據三角測量：
    • 國家級資料：

第 4 章：青光眼治療市場格局

  • 概述
  • PEST分析

第 5 章：青光眼治療市場 - 主要市場動態

  • 青光眼治療市場 - 主要市場動態
  • 市場促進因素
    • 青光眼疾病的發生率不斷上升
    • 產品發布、合作、收購數量不斷增加
  • 市場限制
    • 用藥方案合規性問題
  • 市場機會
    • 穿戴式科技的發展
  • 未來趨勢
    • 新型藥物輸送方法的開發
  • 促進因素和限制的影響：

第 6 章：青光眼治療市場 - 全球市場分析

  • 青光眼治療市場收入，2021-2031
  • 青光眼治療市場預測分析

第 7 章：青光眼治療市場分析 - 按藥物類別

  • BETA受體阻斷劑
  • α腎上腺素激動劑
  • 前列腺素類似物
  • 碳酸酐酶抑制劑
  • 複方藥物
  • 其他

第 8 章：青光眼治療市場分析 - 按適應症

  • 開角型青光眼
  • 閉角型青光眼
  • 其他

第 9 章：青光眼治療市場分析 - 按配銷通路

  • 醫院藥房
  • 零售藥房
  • 網路藥房

第 10 章：青光眼治療市場 - 地理分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 亞太地區其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 南非
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地區

第 11 章：青光眼治療市場 - 產業格局

  • 青光眼治療市場的成長策略
  • 有機成長策略
    • 概述
  • 無機成長策略
    • 概述

第 12 章：公司簡介

  • Alcon AG
  • AbbVie Inc
  • Bausch & Lomb Inc
  • Fera Pharmaceuticals, LLC
  • Viatris Inc
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd
  • Thea Pharma Inc
  • Santen Pharmaceutical Co., Ltd.

第 13 章：附錄

Product Code: TIPRE00018828

The glaucoma therapeutics market was valued at US$ 6.24 billion in 2023 and is expected to reach US$ 8.02 billion by 2031; it is estimated to record a CAGR of 3.2% during 2023-2031.

Key factors driving the market growth are the growing prevalence of glaucoma, rising awareness and early diagnosis of the disease, and increasing product launches are expected to drive the market growth. However, compliance issues with medication regimens and the high cost of treatments hinder the glaucoma therapeutics market growth.

Market Trends of the Glaucoma Therapeutics Market:

The gradual damage of the optic nerve-typically associated with high pressure inside the eye (intraocular pressure)-predominantly due to aging can lead to a group of eye diseases called Glaucoma, which can eventually result in irreversible blindness. One of the most common treatments for glaucoma is to reduce intraocular pressure by using eye drops. However, patient adherence to these eye drops can be challenging, and inadequate patient education can impede treatment success. Additionally, ocular hypotensive drugs can cause local and systemic side effects that may further complicate the treatment. Rising focus on the development of improved formulations with enhanced stability, longer circulation times, and targeted binding properties is likely to add novel products to the market. Recent advancements in glaucoma therapeutics have revolutionized the available treatments in the market. The use of nanoparticles with suitable structures and superior binding capabilities facilitates the bioavailability and efficacy of the drug. Sustained-release (SR) implants and other innovative drug delivery systems offer improved patient compliance and reduced side effects compared to conventional eye drops. Several companies are developing SR drug delivery systems as an alternative to topical delivery to potentially overcome barriers in treating POAG. As per the article published in PubMed Central in 2022, the only approved SR therapy for POAG by the Food and Drug Administration (FDA) is Bimatoprost SR (DurystaTM) from Allergan plc. Other SR therapies including bimatoprost ocular ring (Allergan), iDose (Glaukos Corporation), ENV515 (Envisia Therapeutics), OTX-TP (Ocular Therapeutix), OTX-TIC (Ocular Therapeutix), and latanoprost free acid SR (PolyActiva) are under investigation. SR drug delivery technology in POAG management may shift treatment paradigms and dramatically improve outcomes. Therefore, the development of novel drug delivery methods and combination therapies is likely to remain a key trend in the glaucoma therapeutics market.

Glaucoma therapeutics Market: Segmental Overview

The glaucoma therapeutics market is segmented on the basis of drug class, indication, and distribution channel.

By drug class, the market is divided into beta blockers, alpha-adrenergic agonists, prostaglandin analogs, carbonic anhydrase inhibitors, combination drugs, and others. The prostaglandin analogs segment held a larger market share in 2023. Prostaglandin analogs are the first-line treatment for high intraocular pressure in glaucoma patients. They offer a once-a-day dosing, a significant reduction in intraocular pressure, and low systemic side effects. Thus, the benefits of prostaglandin analogs are responsible for the expansion of the glaucoma therapeutics market size.

The market, by indication, is segmented into open angle glaucoma, angle closure glaucoma, and others. The open-angle glaucoma segment held the largest glaucoma therapeutics market share in 2023 and is projected to register the highest CAGR from 2023 to 2031. Open-angle glaucoma is the most common form of glaucoma, which affects approximately 95% of individuals. Initially, it does not show any symptoms. However, at some point, an individual may start losing their side (peripheral) vision without treatment, resulting in total blindness.

By distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment dominated the market in 2023.

Glaucoma therapeutics Market: Geographical Overview

The scope of the glaucoma therapeutics market report entails North America (the US, Canada, and Mexico), Europe (Spain, the UK, Germany, France, Italy, and the Rest of Europe), Asia Pacific (South Korea, China, India, Japan, Australia, and the Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America). Asia Pacific is expected to register the fastest CAGR in the market from 2023 to 2031. Factors such as ongoing clinical studies for developing novel glaucoma therapies, as well as increasing healthcare expenditures in the region, contribute to the glaucoma therapeutics market growth in Asia Pacific. In terms of revenue, North America accounted for the largest glaucoma therapeutics market share in 2023.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macro-economic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country level data:

4. Glaucoma Therapeutics Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis

5. Glaucoma Therapeutics Market - Key Market Dynamics

  • 5.1 Glaucoma Therapeutics Market - Key Market Dynamics
  • 5.2 Market Drivers
    • 5.2.1 Mounting Incidence of Glaucoma Disease
    • 5.2.2 Increasing Number of Product Launches, Collaborations, Acquisitions
  • 5.3 Market Restraints
    • 5.3.1 Medication Regimen Compliance Issues
  • 5.4 Market Opportunities
    • 5.4.1 Development of Wearable Technologies
  • 5.5 Future Trends
    • 5.5.1 Development of Novel Drug Delivery Methods
  • 5.6 Impact of Drivers and Restraints:

6. Glaucoma Therapeutics Market - Global Market Analysis

  • 6.1 Glaucoma Therapeutics Market Revenue (US$ Million), 2021-2031
  • 6.2 Glaucoma Therapeutics Market Forecast Analysis

7. Glaucoma Therapeutics Market Analysis - by Drug Class

  • 7.1 Beta Blockers
    • 7.1.1 Overview
    • 7.1.2 Beta Blockers: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.2 Alpha Adrenergic Agonists
    • 7.2.1 Overview
    • 7.2.2 Alpha Adrenergic Agonists: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.3 Prostaglandins Analogues
    • 7.3.1 Overview
    • 7.3.2 Prostaglandins Analogues: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.4 Carbonic Anhydrase Inhibitors
    • 7.4.1 Overview
    • 7.4.2 Carbonic Anhydrase Inhibitors: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.5 Combination Drugs
    • 7.5.1 Overview
    • 7.5.2 Combination Drugs: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.6 Others
    • 7.6.1 Overview
    • 7.6.2 Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)

8. Glaucoma Therapeutics Market Analysis - by Indication

  • 8.1 Open Angle Glaucoma
    • 8.1.1 Overview
    • 8.1.2 Open Angle Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.2 Angle Closure Glaucoma
    • 8.2.1 Overview
    • 8.2.2 Angle Closure Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.3 Others
    • 8.3.1 Overview
    • 8.3.2 Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)

9. Glaucoma Therapeutics Market Analysis - by Distribution Channel

  • 9.1 Hospital Pharmacy
    • 9.1.1 Overview
    • 9.1.2 Hospital Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.2 Retail Pharmacy
    • 9.2.1 Overview
    • 9.2.2 Retail Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.3 Online Pharmacy
    • 9.3.1 Overview
    • 9.3.2 Online Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)

10. Glaucoma Therapeutics Market - Geographical Analysis

  • 10.1 Overview
  • 10.2 North America
    • 10.2.1 North America Glaucoma Therapeutics Market Overview
    • 10.2.2 North America: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    • 10.2.3 North America: Glaucoma Therapeutics Market Breakdown, by Drug Class
      • 10.2.3.1 North America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Drug Class
    • 10.2.4 North America: Glaucoma Therapeutics Market Breakdown, by Indication
      • 10.2.4.1 North America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Indication
    • 10.2.5 North America: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 10.2.5.1 North America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Distribution Channel
    • 10.2.6 North America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
      • 10.2.6.1 North America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
      • 10.2.6.2 United States: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.2.6.2.1 United States: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 10.2.6.2.2 United States: Glaucoma Therapeutics Market Breakdown, by Indication
        • 10.2.6.2.3 United States: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 10.2.6.3 Canada: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.2.6.3.1 Canada: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 10.2.6.3.2 Canada: Glaucoma Therapeutics Market Breakdown, by Indication
        • 10.2.6.3.3 Canada: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 10.2.6.4 Mexico: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.2.6.4.1 Mexico: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 10.2.6.4.2 Mexico: Glaucoma Therapeutics Market Breakdown, by Indication
        • 10.2.6.4.3 Mexico: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
  • 10.3 Europe
    • 10.3.1 Europe Glaucoma Therapeutics Market Overview
    • 10.3.2 Europe: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    • 10.3.3 Europe: Glaucoma Therapeutics Market Breakdown, by Drug Class
      • 10.3.3.1 Europe: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Drug Class
    • 10.3.4 Europe: Glaucoma Therapeutics Market Breakdown, by Indication
      • 10.3.4.1 Europe: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Indication
    • 10.3.5 Europe: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 10.3.5.1 Europe: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Distribution Channel
    • 10.3.6 Europe: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
      • 10.3.6.1 Europe: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
      • 10.3.6.2 Germany: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.3.6.2.1 Germany: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 10.3.6.2.2 Germany: Glaucoma Therapeutics Market Breakdown, by Indication
        • 10.3.6.2.3 Germany: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 10.3.6.3 France: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.3.6.3.1 France: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 10.3.6.3.2 France: Glaucoma Therapeutics Market Breakdown, by Indication
        • 10.3.6.3.3 France: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 10.3.6.4 United Kingdom: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.3.6.4.1 United Kingdom: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 10.3.6.4.2 United Kingdom: Glaucoma Therapeutics Market Breakdown, by Indication
        • 10.3.6.4.3 United Kingdom: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 10.3.6.5 Italy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.3.6.5.1 Italy: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 10.3.6.5.2 Italy: Glaucoma Therapeutics Market Breakdown, by Indication
        • 10.3.6.5.3 Italy: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 10.3.6.6 Spain: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.3.6.6.1 Spain: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 10.3.6.6.2 Spain: Glaucoma Therapeutics Market Breakdown, by Indication
        • 10.3.6.6.3 Spain: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 10.3.6.7 Rest of Europe: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.3.6.7.1 Rest of Europe: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 10.3.6.7.2 Rest of Europe: Glaucoma Therapeutics Market Breakdown, by Indication
        • 10.3.6.7.3 Rest of Europe: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
  • 10.4 Asia Pacific
    • 10.4.1 Asia Pacific Glaucoma Therapeutics Market Overview
    • 10.4.2 Asia Pacific: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    • 10.4.3 Asia Pacific: Glaucoma Therapeutics Market Breakdown, by Drug Class
      • 10.4.3.1 Asia Pacific: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Drug Class
    • 10.4.4 Asia Pacific: Glaucoma Therapeutics Market Breakdown, by Indication
      • 10.4.4.1 Asia Pacific: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Indication
    • 10.4.5 Asia Pacific: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 10.4.5.1 Asia Pacific: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Distribution Channel
    • 10.4.6 Asia Pacific: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
      • 10.4.6.1 Asia Pacific: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
      • 10.4.6.2 China: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.4.6.2.1 China: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 10.4.6.2.2 China: Glaucoma Therapeutics Market Breakdown, by Indication
        • 10.4.6.2.3 China: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 10.4.6.3 Japan: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.4.6.3.1 Japan: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 10.4.6.3.2 Japan: Glaucoma Therapeutics Market Breakdown, by Indication
        • 10.4.6.3.3 Japan: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 10.4.6.4 India: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.4.6.4.1 India: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 10.4.6.4.2 India: Glaucoma Therapeutics Market Breakdown, by Indication
        • 10.4.6.4.3 India: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 10.4.6.5 Australia: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.4.6.5.1 Australia: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 10.4.6.5.2 Australia: Glaucoma Therapeutics Market Breakdown, by Indication
        • 10.4.6.5.3 Australia: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 10.4.6.6 South Korea: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.4.6.6.1 South Korea: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 10.4.6.6.2 South Korea: Glaucoma Therapeutics Market Breakdown, by Indication
        • 10.4.6.6.3 South Korea: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 10.4.6.7 Rest of APAC: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.4.6.7.1 Rest of APAC: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 10.4.6.7.2 Rest of APAC: Glaucoma Therapeutics Market Breakdown, by Indication
        • 10.4.6.7.3 Rest of APAC: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
  • 10.5 Middle East and Africa
    • 10.5.1 Middle East and Africa Glaucoma Therapeutics Market Overview
    • 10.5.2 Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    • 10.5.3 Middle East and Africa: Glaucoma Therapeutics Market Breakdown, by Drug Class
      • 10.5.3.1 Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Drug Class
    • 10.5.4 Middle East and Africa: Glaucoma Therapeutics Market Breakdown, by Indication
      • 10.5.4.1 Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Indication
    • 10.5.5 Middle East and Africa: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 10.5.5.1 Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Distribution Channel
    • 10.5.6 Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
      • 10.5.6.1 Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
      • 10.5.6.2 Saudi Arabia: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.5.6.2.1 Saudi Arabia: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 10.5.6.2.2 Saudi Arabia: Glaucoma Therapeutics Market Breakdown, by Indication
        • 10.5.6.2.3 Saudi Arabia: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 10.5.6.3 South Africa: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.5.6.3.1 South Africa: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 10.5.6.3.2 South Africa: Glaucoma Therapeutics Market Breakdown, by Indication
        • 10.5.6.3.3 South Africa: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 10.5.6.4 United Arab Emirates: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.5.6.4.1 United Arab Emirates: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 10.5.6.4.2 United Arab Emirates: Glaucoma Therapeutics Market Breakdown, by Indication
        • 10.5.6.4.3 United Arab Emirates: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 10.5.6.5 Rest of Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.5.6.5.1 Rest of Middle East and Africa: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 10.5.6.5.2 Rest of Middle East and Africa: Glaucoma Therapeutics Market Breakdown, by Indication
        • 10.5.6.5.3 Rest of Middle East and Africa: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
  • 10.6 South and Central America
    • 10.6.1 South and Central America Glaucoma Therapeutics Market Overview
    • 10.6.2 South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    • 10.6.3 South and Central America: Glaucoma Therapeutics Market Breakdown, by Drug Class
      • 10.6.3.1 South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Drug Class
    • 10.6.4 South and Central America: Glaucoma Therapeutics Market Breakdown, by Indication
      • 10.6.4.1 South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Indication
    • 10.6.5 South and Central America: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 10.6.5.1 South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Distribution Channel
    • 10.6.6 South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
      • 10.6.6.1 South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
      • 10.6.6.2 Brazil: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.6.6.2.1 Brazil: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 10.6.6.2.2 Brazil: Glaucoma Therapeutics Market Breakdown, by Indication
        • 10.6.6.2.3 Brazil: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 10.6.6.3 Argentina: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.6.6.3.1 Argentina: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 10.6.6.3.2 Argentina: Glaucoma Therapeutics Market Breakdown, by Indication
        • 10.6.6.3.3 Argentina: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 10.6.6.4 Rest of South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.6.6.4.1 Rest of South and Central America: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 10.6.6.4.2 Rest of South and Central America: Glaucoma Therapeutics Market Breakdown, by Indication
        • 10.6.6.4.3 Rest of South and Central America: Glaucoma Therapeutics Market Breakdown, by Distribution Channel

11. Glaucoma Therapeutics Market - Industry Landscape

  • 11.1 Growth Strategies in Glaucoma Therapeutics Market
  • 11.2 Organic Growth Strategies
    • 11.2.1 Overview
  • 11.3 Inorganic Growth Strategies
    • 11.3.1 Overview

12. Company Profiles

  • 12.1 Alcon AG
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 AbbVie Inc
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Bausch & Lomb Inc
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Fera Pharmaceuticals, LLC
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 Viatris Inc
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 Novartis AG
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 Sun Pharmaceutical Industries Ltd
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 Teva Pharmaceutical Industries Ltd
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 Thea Pharma Inc
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments
  • 12.10 Santen Pharmaceutical Co., Ltd.
    • 12.10.1 Key Facts
    • 12.10.2 Business Description
    • 12.10.3 Products and Services
    • 12.10.4 Financial Overview
    • 12.10.5 SWOT Analysis
    • 12.10.6 Key Developments

13. Appendix

  • 13.1 About The Insight Partners
  • 13.2 Glossary of Terms

List Of Tables

  • Table 1. Glaucoma Therapeutics Market Segmentation
  • Table 2. Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Table 3. Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Class
  • Table 4. Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Indication
  • Table 5. Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 6. North America: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 7. North America: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 8. North America: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 9. North America: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Country
  • Table 10. United States: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 11. United States: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 12. United States: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 13. Canada: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 14. Canada: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 15. Canada: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 16. Mexico: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 17. Mexico: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 18. Mexico: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 19. Europe: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 20. Europe: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 21. Europe: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 22. Europe: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Country
  • Table 23. Germany: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 24. Germany: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 25. Germany: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 26. France: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 27. France: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 28. France: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 29. United Kingdom: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 30. United Kingdom: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 31. United Kingdom: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 32. Italy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 33. Italy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 34. Italy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 35. Spain: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 36. Spain: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 37. Spain: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 38. Rest of Europe: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 39. Rest of Europe: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 40. Rest of Europe: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 41. Asia Pacific: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 42. Asia Pacific: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 43. Asia Pacific: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 44. Asia Pacific: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Country
  • Table 45. China: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 46. China: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 47. China: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 48. Japan: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 49. Japan: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 50. Japan: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 51. India: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 52. India: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 53. India: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 54. Australia: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 55. Australia: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 56. Australia: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 57. South Korea: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 58. South Korea: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 59. South Korea: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 60. Rest of APAC: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 61. Rest of APAC: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 62. Rest of APAC: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 63. Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 64. Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 65. Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 66. Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Country
  • Table 67. Saudi Arabia: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 68. Saudi Arabia: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 69. Saudi Arabia: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 70. South Africa: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 71. South Africa: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 72. South Africa: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 73. United Arab Emirates: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 74. United Arab Emirates: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 75. United Arab Emirates: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 76. Rest of Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 77. Rest of Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 78. Rest of Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 79. South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 80. South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 81. South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 82. South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Country
  • Table 83. Brazil: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 84. Brazil: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 85. Brazil: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 86. Argentina: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 87. Argentina: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 88. Argentina: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 89. Rest of South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 90. Rest of South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 91. Rest of South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 92. Recent Organic Growth Strategies in Glaucoma Therapeutics Market
  • Table 93. Recent Inorganic Growth Strategies in the Glaucoma Therapeutics Market
  • Table 94. Glossary of Terms, Transiaent Protein Expression Market

List Of Figures

  • Figure 1. Glaucoma Therapeutics Market Segmentation, by Geography
  • Figure 2. PEST Analysis
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Glaucoma Therapeutics Market Revenue (US$ Million), 2021-2031
  • Figure 5. Glaucoma Therapeutics Market Share (%) - by Drug Class (2023 and 2031)
  • Figure 6. Beta Blockers: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 7. Alpha Adrenergic Agonists: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 8. Prostaglandins Analogues: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 9. Carbonic Anhydrase Inhibitors: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 10. Combination Drugs: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 11. Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 12. Glaucoma Therapeutics Market Share (%) - by Indication (2023 and 2031)
  • Figure 13. Open Angle Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 14. Angle Closure Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 15. Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 16. Glaucoma Therapeutics Market Share (%) - by Distribution Channel (2023 and 2031)
  • Figure 17. Hospital Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 18. Retail Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 19. Online Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 20. Glaucoma Therapeutics Market Breakdown by Region, 2023 and 2031 (%)
  • Figure 21. North America: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 22. North America: Glaucoma Therapeutics Market Breakdown, by Drug Class (2023 and 2031)
  • Figure 23. North America: Glaucoma Therapeutics Market Breakdown, by Indication (2023 and 2031)
  • Figure 24. North America: Glaucoma Therapeutics Market Breakdown, by Distribution Channel (2023 and 2031)
  • Figure 25. North America: Glaucoma Therapeutics Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 26. United States: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 27. Canada: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 28. Mexico: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 29. Europe: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 30. Europe: Glaucoma Therapeutics Market Breakdown, by Drug Class (2023 and 2031)
  • Figure 31. Europe: Glaucoma Therapeutics Market Breakdown, by Indication (2023 and 2031)
  • Figure 32. Europe: Glaucoma Therapeutics Market Breakdown, by Distribution Channel (2023 and 2031)
  • Figure 33. Europe: Glaucoma Therapeutics Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 34. Germany: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 35. France: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 36. United Kingdom: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 37. Italy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 38. Spain: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 39. Rest of Europe: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 40. Asia Pacific: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 41. Asia Pacific: Glaucoma Therapeutics Market Breakdown, by Drug Class (2023 and 2031)
  • Figure 42. Asia Pacific: Glaucoma Therapeutics Market Breakdown, by Indication (2023 and 2031)
  • Figure 43. Asia Pacific: Glaucoma Therapeutics Market Breakdown, by Distribution Channel (2023 and 2031)
  • Figure 44. Asia Pacific: Glaucoma Therapeutics Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 45. China: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 46. Japan: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 47. India: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 48. Australia: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 49. South Korea: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 50. Rest of APAC: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 51. Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 52. Middle East and Africa: Glaucoma Therapeutics Market Breakdown, by Drug Class (2023 and 2031)
  • Figure 53. Middle East and Africa: Glaucoma Therapeutics Market Breakdown, by Indication (2023 and 2031)
  • Figure 54. Middle East and Africa: Glaucoma Therapeutics Market Breakdown, by Distribution Channel (2023 and 2031)
  • Figure 55. Middle East and Africa: Glaucoma Therapeutics Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 56. Saudi Arabia: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 57. South Africa: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 58. United Arab Emirates: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 59. Rest of Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 60. South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 61. South and Central America: Glaucoma Therapeutics Market Breakdown, by Drug Class (2023 and 2031)
  • Figure 62. South and Central America: Glaucoma Therapeutics Market Breakdown, by Indication (2023 and 2031)
  • Figure 63. South and Central America: Glaucoma Therapeutics Market Breakdown, by Distribution Channel (2023 and 2031)
  • Figure 64. South and Central America: Glaucoma Therapeutics Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 65. Brazil: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 66. Argentina: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 67. Rest of South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 68. Growth Strategies in Glaucoma Therapeutics Market